Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novacept NovaSure To Compete With Ethicon In U.S. Menorrhagia Market

This article was originally published in The Gray Sheet

Executive Summary

The relatively short procedure time required for endometrial ablation with Novacept's NovaSure device will prove a key advantage over other menorrhagia treatment systems, the firm maintains.
Advertisement

Related Content

Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
CDRH Turns In Strong Performance For Premarket Reviews In Fiscal Year 2001
CDRH Turns In Strong Performance For Premarket Reviews In Fiscal Year 2001
Advertisement
UsernamePublicRestriction

Register

MT015552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel